FIELD: pharmaceuticals.
SUBSTANCE: present invention relates to hydrochloride salt, citrate salt, phosphate salt or sulphate salt of compound 1, as well as to crystalline forms of said salts and a method for production thereof.
EFFECT: disclosed compound is intended for preparing a medicament for treating cerebral stroke or epilepsy.
20 cl, 9 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| CRYSTALLINE OR AMORPHOUS FORM OF FXR AGONISTS BEING STEROID DERIVATIVES, THEIR PRODUCTION METHOD AND THEIR USE | 2018 |
|
RU2800751C2 |
| LSD1 INHIBITOR SALT AND ITS POLYMORPHIC FORM | 2019 |
|
RU2794977C2 |
| SALT FORM OF ISOQUINOLINONE TYPE COMPOUND AS ROCK INHIBITOR AND METHOD FOR ITS PREPARATION | 2021 |
|
RU2821792C1 |
| SOLID FORM, CRYSTALLINE, AND CRYSTALLINE A OF FXR AGONIST AND METHOD FOR THEIR PRODUCTION AND THEIR APPLICATION | 2019 |
|
RU2804320C2 |
| INDAZOLE DERIVATIVE SALTS AND THEIR CRYSTALS | 2017 |
|
RU2747399C2 |
| COMPOUND OF BRD4 INHIBITOR IN SOLID FORM, METHOD FOR ITS PRODUCTION AND APPLICATION | 2020 |
|
RU2793346C1 |
| CRYSTAL FORM OF PHOSPHODIESTERASE INHIBITOR, METHOD OF ITS PREPARATION AND USE | 2020 |
|
RU2814498C2 |
| ACID ADDITION SALT OF TRK INHIBITING COMPOUND | 2015 |
|
RU2708236C2 |
| COMPOUND OF FGFR INHIBITOR IN SOLID FORM AND METHOD OF ITS PREPARATION | 2020 |
|
RU2810067C2 |
| PYRIDO[1,2-A]PYRIMIDONE ANALOG, ITS CRYSTAL FORM, ITS INTERMEDIATE COMPOUND AND METHOD FOR THEIR PREPARATION | 2016 |
|
RU2753696C2 |
